22 Enrolled - Daiichi Sankyo TIMI 48 ENGAGE

With this long-term Atrial Fibrillation trial, 22 patients were enrolled at Katy Cardiology, most of whom remained in the trial for over 3 years to help Daaichi determine if Edoxaban was superior to Warfarin, among other things. 

TIMI 48: Global Study to Assess the Safety and Effectiveness of DU-176b vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation.